PDCD1 and susceptibility to pneumonia measurement: Another retrospective study published by Naidoo and colleagues showed an increase in the incidence of pneumonia among patients receiving anti-PD1/anti-PD-L1 monotherapy and/or in combination with anti-CTLA4 [16].